"Designing Growth Strategies is in our DNA"
Inflammatory Bowel Disease (IBD) is used to represent a group of intestinal disorders that cause prolonged inflammation of the digestive tract. The digestive tract comprises of a number of key organs such as the mouth, esophagus, stomach, small intestine, and large intestine and is responsible for the breaking down of food, extraction of nutrients and the removal of waste products. The major types of diseases that comprise of Inflammatory Bowel Disease (IBD) include ulcerative colitis and Crohn’s Disease. The causes of Inflammatory Bowel Disease (IBD) remain unclear but some of the factors attributing to it include genetics and the immune system. Inflammatory Bowel Disease (IBD) has a number of associated complications such as colon cancer, obstructive bowel, skin, eye & joint inflammation, malnutrition and ulcers. The treatment for Inflammatory Bowel Disease (IBD) typically includes drug therapy such as anti-inflammatory drugs, immune system suppressors & antibiotics, surgery and lifestyle management.
The global inflammatory bowel diseases (IBD) therapeutics market is anticipated to grow owing to a number of factors such as the increasing incidences of ulcerative colitis & crohn’s disease, increasing adoption of anti-inflammatory drugs, growing demand for preventive care to avoid associated disorders such as cancers. According to the Centre for Disease Control and Prevention (CDC), in 2015, an estimated 1.3% of U.S. adults were diagnosed with inflammatory bowel disease (IBD), either crohn’s disease or ulcerative colitis. As compared with adults without the disease, individuals with inflammatory bowel disease (IBD) are more likely to have chronic health conditions such as cardiovascular disease, respiratory disease, cancer, arthritis, kidney disease, and liver disease. These factors are expected to positively drive the market growth.
To gain extensive insights into the market, Request for Customization
The factors limiting the growth of the global inflammatory bowel disease (IBD) therapeutics market are the high-cost treatments, lack of diagnosis or misdiagnosis and the associated side effects of the therapeutics.
Some of the major companies operating in the global inflammatory bowel diseases (IBD) therapeutics market are AbbVie Inc., Pfizer Inc., Shire, Janssen Pharmaceuticals, Inc., ALLERGAN, Novartis AG, GlaxoSmithKline Plc and Merck & Co., Inc. and others.
· TNF inhibitors
By Disease Indication
· Crohn’s Disease
· Ulcerative Colitis
By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Among the segmentation, immunomodulators in the product segment are expected to hold a significant share of the global inflammatory bowel diseases therapeutics market. Moreover, the higher prevalence of ulcerative colitis among the disease indication segment is projected to hold a considerable share of the global inflammatory bowel diseases therapeutics market by 2026.
Prevalence of inflammatory bowel disease for key countries
Key strategies of leading market players
Recent industry developments such as partnerships, mergers, and acquisitions
North America is projected to dominate the global inflammatory bowel diseases therapeutics market owing to rapidly increasing prevalence of inflammatory bowel disease and high availability of treatment options. Moreover, high expenditure on healthcare and prevalence of diagnostic measures leading to early diagnosis of the disease and established healthcare system is anticipated to register considerable share of the global inflammatory bowel diseases therapeutics market during the forecast period. Asia Pacific holds huge potential for growth of the global inflammatory bowel diseases therapeutics market owing to the higher prevalence of ulcerative colitis as well as crohn’s disease. Additionally, rise in risk factors associated with the inflammatory bowel disease such as smoking, alcoholism, sedentary lifestyle and consumption of non-nutritious food may boost the prevalence of inflammatory bowel disease, which is projected to drive the market by 2026.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry